Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05472688 · ClinicalTrials.gov registry record
My Baby Biome: Infant Stool Samples for Microbiome Health (MBB)
A clinical trial of Dysbiosis, sponsored by Persephone Biosciences.
- Active
- Registry status
- 430
- Enrollment target
- 1
- Study location
NCT05472688: Active study of Dysbiosis, sponsored by Persephone Biosciences.
NCT05472688 is a study of Dysbiosis that is active but no longer recruiting, run by Persephone Biosciences. The registered enrollment target is 430 participants, above the 81-participant average among 13 other Dysbiosis trials with a reported enrollment target (431% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05472688, a study of Dysbiosis, is active but no longer recruiting, sponsored by Persephone Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- 430 participants
- Enrollment target
- 1
- Study location
Study Summary
My Baby Biome is an observational study that will use 600 infant stool samples to determine the biomarkers associated with a healthy infant gut. Biomarkers identified in this study will be used to develop precision probiotics and LBPs for improving infant gut health outcomes to the benefit of all infants. Parents will be asked to submit follow-up questionnaires regarding infant immune health to improve insights obtained from the data.
Primary Outcome
Stool samples will be analyzed for bacterial metagenomics, metabolomics, proteomics, and transcriptomics to define biomarkers (such as bacteria or proteins) that are correlated with healthy infants as defined by the accompanying questionnaire.
Conditions Studied
Study Locations (1)
California
- Persephone Biosciences, Inc. - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2029-12-31 |
What the registry record for NCT05472688 still lists
NCT05472688 is an observational study that tracks outcomes without assigning an intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap, above the 81-participant average among 13 other Dysbiosis trials with a reported enrollment target (431% higher).
The record links to 1 condition, with Dysbiosis appearing as the primary indexed condition, and to 0 interventions.
NCT05472688 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05472688 about?
NCT05472688 is a clinical study titled "My Baby Biome: Infant Stool Samples for Microbiome Health (MBB)". My Baby Biome is an observational study that will use 600 infant stool samples to determine the biomarkers associated with a healthy infant gut. Biomarkers identified in this study will be used to develop precision probiotics and LBPs for improving infant gut health outcomes to the benefit of all in...
What is the current status of trial NCT05472688?
This trial is currently active not recruiting. The enrollment target is 430 participants. The study started on 2022-07-14. Estimated completion is 2029-12-31.
What conditions does trial NCT05472688 study?
This clinical trial studies the following conditions: Dysbiosis.
Who is sponsoring clinical trial NCT05472688?
This trial is sponsored by Persephone Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05472688 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dysbiosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05472688's enrollment target sits among peer trials
430 1st of 13 higher than 13 of 13 other Dysbiosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dysbiosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Peanut Butter on Gut and Metabolic Health
RECRUITING · NA
-
Personalized GI Motility Responses to Diet
RECRUITING · NA
-
Effect of Lentils and Chickpeas on Gut Microbiome and Metabolic Health
RECRUITING · NA
-
A Study of Healthy Microbiome, Healthy Mind
RECRUITING · NA
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Effect of Watermelon on Gut and Cardiometabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
- NCT05844891 · 430 participants · NA
Telehealth-Enhanced Asthma Care for Home After the Emergency Room
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI